Taisho, Ribomic Join To Develop Nucleic Acid-Based Treatments
This article was originally published in PharmAsia News
Executive Summary
Taisho Pharmaceutical has teamed with a Ribomic, a Japan startup drug maker to develop drugs based on nucleic acid for a wide range of treatments, with clinical trials to begin in four years.